Table 2.

Summary of health facility responses in Kulon Progo and Magelang Districts

Question	Answer (%)
Antimalarial materials	Yes		No
antimal_provided	32.3		67.7
antimal_stockout	Yes	No
	25.0	55.0
antimal_stockout_length (months /range)	3.6/1–8
Microscopy materials	Yes		No
microscopy_provided	82.3		17.7
functioning_microscope	Yes	No
	98.0	2.0
functioning_countingmeters	48.0	52.0
microscopy_stockout	13.7	86.3
microscopy_stockout_length	3.6/1–12
RDT materials	Yes		No
rdt_provided	14.5		85.5
rdt_stockout	Yes	No
	44.4	55.6
rdt_stockout_length (months/range)	4.0/1–6
Reference laboratories	Yes		No
reflab_confirm	64.5		35.5
reflab_samples	Yes	No
	53.8	46.2
Microscopy training	Yes		No
microscopy_staff	79.0		21.0
microscopy_training	Yes	No
	89.8	10.2
microscopy_competency	56.8	43.2
microscopy_training_length (years since last /range)	2.9/0.9–16.9
RDT training	Yes		No
rdt_staff	35.5		64.5
rdt_hf_training	Yes	No	52.4
	47.6	52.4
rdt_hf_training_length	3.9/1.8–7.9
	Yes		No
rdt_chw_training	30.6		69.4
rdt_chw_training_length (years since last /range)	1.5/0.9–2.0
Case training	Yes		No
case_training	50.0		50.0
case_training_length (years since last /range)	3.5/0.9–17.0
treatment_sops	61.3		38.7
supervision	30.6		69.4
supervision_lenght (years since last /range)	1.2/0.9–4.9
Case reporting	Yes		No
suspected_record	56.5		43.5
tested_record	56.5		43.5
cases_record	51.6		48.4
vivax_record	51.6		48.4
database_record	32.3		67.7

Responses to each survey question are summarised by proportion of total facilities interviewed (or average and range, in case of numerical values). Not shown in the summary table are descriptions of each facility’s malaria case definition, case and relapse definition for P. vivax, and P. vivax case investigation procedure